↓ Expand ↓

Posts Tagged → Bath salts

DEA jams synthetic marijuana and “bath salts” industry

With all the discord in Washington these days, it’s rare to see several US governmental organizations working together to address a significant public health problem.

This week, the US Drug Enforcement Agency (DEA) mobilized Operation Log Jam, an unusual and highly-coordinated action with six other federal agencies aimed to shut down the synthetic designer drug industry in 109 US cities. The products targeted were of two broad classes: 1) synthetic marijuana “incense” products comprised of naphthoylindole cannabimimetic compounds first synthesized by John W. Huffman’s lab at Clemson in the mid-1990s, and 2) “bath salts” or “plant food” products containing the stimulant/empathogen mephedrone (4-methylmethcathinone) or the stimulant MDPV (3,4-methylenedioxypyrovalerone).

This compilation of posts on synthetic marijuana and, to a lesser extent, “bath salts” serves as a good primer on the subject.

Continue reading →

NC legislators aim to clean up “bath salt” omission

3,4-methylenedioxypyrovalerone (MDPV) - the most common compound found in "bath salts"

Earlier this week, I wrote about on the comprehensive chemistry text in two North Carolina state bills – H12/S9 and H13/S7 – to criminalize distribution, sales, and possession of compounds present in a variety of legal-high, designer drug products.

One bill specifically addressed compounds present in synthetic marijuana compounds whose extensive list included those eponymous JWH compounds synthesized in the laboratory of Clemson University Professor Emeritus, John W. Huffman (featured here). The other bill addressed mephedrone (4-methylmethcathinone; 4-MMC) and other structural analogs of this amphetamine and cathinone derivative.

However, I noted my surprise at the time at the omission of a compound more commonly associated with so-called bath salt products: MDPV, or methylenedioxypyrovalerone. My neuroscience blogging colleague DrugMonkey also remarked to me of his surprise since most other states deal with MDPV in the same legislation with mephedrone/4-MMC because of their structural similarity.

Continue reading →